Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis

被引:22
作者
Chiu, Bin [1 ,5 ]
Tai, Huai-Ching [2 ]
Chung, Shiu-Dong [1 ,2 ,5 ]
Birder, Lori A. [3 ,4 ]
机构
[1] Far Eastern Mem Hosp, Div Urol, Dept Surg, New Taipei 220, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Urol, Taipei 100, Taiwan
[3] Univ Pittsburgh, Dept Med, Sch Med, Renal Electrolyte Div, 930 Scaife Hall, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Sch Med, Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA
[5] Yuan Ze Univ, Coll Informat, Grad Program Biomed Informat, Chungli 320, Taiwan
关键词
cystitis; botulinum toxin A; interstitial cystitis; intravesical injection; HUMAN DETRUSOR OVERACTIVITY; NERVE GROWTH-FACTOR; INTERSTITIAL CYSTITIS; NEUROPATHIC PAIN; INJECTIONS; EXPRESSION; RAT; TRPV1; ONABOTULINUMTOXINA; PATHOGENESIS;
D O I
10.3390/toxins8070201
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Botulinum neurotoxin A (BoNT-A), derived from Clostridium botulinum, has been used clinically for several diseases or syndrome including chronic migraine, spasticity, focal dystonia and other neuropathic pain. Chronic pelvic or bladder pain is the one of the core symptoms of bladder pain syndrome/interstitial cystitis (BPS/IC). However, in the field of urology, chronic bladder or pelvic pain is often difficult to eradicate by oral medications or bladder instillation therapy. We are looking for new treatment modality to improve bladder pain or associated urinary symptoms such as frequency and urgency for patients with BPS/IC. Recent studies investigating the mechanism of the antinociceptive effects of BoNT A suggest that it can inhibit the release of peripheral neurotransmitters and inflammatory mediators from sensory nerves. In this review, we will examine the evidence supporting the use of BoNTs in bladder pain from basic science models and review the clinical studies on therapeutic applications of BoNT for BPS/IC.
引用
收藏
页数:5
相关论文
共 36 条
[1]   Botulinum toxin typeA injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response [J].
Akiyama, Yoshiyuki ;
Nomiya, Akira ;
Niimi, Aya ;
Yamada, Yukio ;
Fujimura, Tetsuya ;
Nakagawa, Tohru ;
Fukuhara, Hiroshi ;
Kume, Haruki ;
Igawa, Yasuhiko ;
Homma, Yukio .
INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (09) :835-841
[2]   Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity [J].
Apostolidis, A ;
Dasgupta, P ;
Fowler, CJ .
EUROPEAN UROLOGY, 2006, 49 (04) :644-650
[3]   Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity [J].
Apostolidis, A ;
Popat, R ;
Yiangou, Y ;
Cockayne, D ;
Ford, APDW ;
Davis, JB ;
Dasgupta, P ;
Fowler, CJ ;
Anand, P .
JOURNAL OF UROLOGY, 2005, 174 (03) :977-982
[4]   Vanilloid receptor 1 expression in the rat urinary tract [J].
Avelino, A ;
Cruz, C ;
Nagy, I ;
Cruz, F .
NEUROSCIENCE, 2002, 109 (04) :787-798
[5]   Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat [J].
Chuang, Yao-Chi ;
Yoshimura, Naoki ;
Huang, Chao-Cheng ;
Wu, Moya ;
Chiang, Po-Hui ;
Chancellor, Michael B. .
JOURNAL OF UROLOGY, 2008, 180 (02) :742-748
[6]  
Chuang YC, 2004, J UROLOGY, V172, P1529, DOI 10.1097/01.ju.0000137844.77524.97
[7]  
Chung SD, 2012, PAIN PHYSICIAN, V15, P197
[8]   Subcutaneous administration of botulinum toxin A reduces formalin-induced pain [J].
Cui, ML ;
Khanijou, S ;
Rubino, J ;
Aoki, KR .
PAIN, 2004, 107 (1-2) :125-133
[9]   Epidemiology of interstitial cystitis: A population based study [J].
Curhan, GC ;
Speizer, FE ;
Hunter, DJ ;
Curhan, SG ;
Stampfer, MJ .
JOURNAL OF UROLOGY, 1999, 161 (02) :549-552
[10]   Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy [J].
Durham, PL ;
Cady, R ;
Cady, R .
HEADACHE, 2004, 44 (01) :35-42